Calidi Biotherapeutics Advances RedTail Platform with In Situ T-Cell Engager Data — Calidi Biotherapeutics, Inc.

Event summary

Calidi Biotherapeutics presented new data on CLD-501, its in situ T-cell engager candidate targeting TROP-2, at the T-Cell Engager Therapeutic Summit on June 24, 2026.
The RedTail platform demonstrated the ability to express both a functional T-cell engager and IL-15 superagonist in the tumor microenvironment (TME).
CLD-401, the lead candidate from the RedTail platform, is expected to file an IND by the end of 2026.
Calidi is pursuing additional T-cell engager targets like EGFR, EpCAM, and Nectin-4.

The big picture

Calidi Biotherapeutics is addressing a central challenge in immuno-oncology: delivering tumor-specific T-cell engagers effectively in solid tumors. The company's RedTail platform aims to remodel the tumor microenvironment and enable high-level expression of therapeutic genetic payloads directly at the tumor site, potentially overcoming limitations that have hindered previous T-cell engager therapies. This strategic focus on in situ activation and expression could position Calidi as a key player in the evolving landscape of targeted cancer therapies.

What we're watching

Clinical Progress: Whether Calidi can successfully file an IND for CLD-401 by the end of 2026 and advance its pipeline.
Strategic Partnerships: The pace at which Calidi secures partnerships to accelerate clinical development and broaden the impact of its RedTail platform.
Market Differentiation: How effectively Calidi can overcome historical limitations of T-cell engagers in solid tumors through its RedTail approach.